Logo

Altana Licenses Spotfire DecisionSite Software

Nov 01, 2004

NEW YORK, Nov. 1 (GenomeWeb News) - Spotfire today said that Altana Pharma has licensed its Spotfire DecisionSite software worldwide for research, lead discovery, and clinical safety in four separate labs.

The drug maker currently uses the software in functional genomics and lead discovery research, Spotfire said.

 

Altana will integrate DecisionSite into its research portal, and said it plans to use Spotfire's posters as a global reporting platform to "publish, share, and extend" DecisionSite analysis results across project teams.

Breaking News
The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.